CLINICAL and SEROLOGICAL EVOLUTION of RHEUMATIC PATIENTS INFECTED by SARS-COV-2
Annals of the Rheumatic Diseases
; 81:1699-1700, 2022.
Article
in English
| EMBASE | ID: covidwho-2009132
ABSTRACT
Background:
SARS-CoV-2 infection is a public health problem due to its high contagiousness and mortality. Spectrum of symptoms ranges from no symptoms to interstitial pneumonia. Patients with rheumatic disease present an increased infectious risk, especially those treated with immunosuppressants or biologic therapy. Since the beginning of the pandemic, risk of contagion and development of complications in these patients has been questioned.Objectives:
To describe hospitalization prevalence, seroconversion, and symptoms in patients under follow-up by the rheumatology department of a tertiary hospital.Methods:
Observational, cross-sectional study conducted by phone interview including patients with different diagnosis of rhematic diseases. Data about symptoms, hospital admission, serology by ELISA (when >15 days of evolution), diagnosis and baseline treatment, from March 2020 to February 2021 were collected.Results:
Eighty-six patients with different rheumatic diseases and positive COVID-19 PCR were included (82.35% women) in Table 1. Mean age was 49.30 years (16.16). The 48.71% received biological therapy, JAK inhibitors or apremi-last, with a median of 3.11 years (Q1 1,08;Q3 3,17). Secukinumab was the biological therapy most often used (24,32%), followed by Tocilizumab (13,51%). The 34,18% received DMARDs or immunosuppressors, with a median of 5.09 years (Q1 12,25;Q3 11.09). The most frequent symptoms were asthenia (72.15%), headache (66.23%) and cough (59.49%). Nine patients (11.25%) were admitted to hospital, eight of them (10%) for pneumonia. Three of them were admitted to intensive care and one died. Seroconversion occurred in 53.25%. low IgG titers were present in 2.94% and IgM persisted positive in 56.25% of this group. In 6.45% the result was indeterminate.Conclusion:
Hospitalization and mortality rate obtained was low and the most frequent symptoms were mild. Seroconversion occurred in more than 50% of patients and the result of 6.45% was indeterminate. It's important to highlight that since March 2020 to May 2020 IgG positive prevalence was 25%, while since September 2021 to February 2021, this prevalence increased until 57,45%. This difference is due to a modifcation of autoantibody detection technique since summer 2020.
autoantibody; disease modifying antirheumatic drug; endogenous compound; immunoglobulin G; immunoglobulin M; immunosuppressive agent; Janus kinase inhibitor; secukinumab; tocilizumab; adult; asthenia; complication; conference abstract; controlled study; coronavirus disease 2019; coughing; cross-sectional study; drug therapy; enzyme linked immunosorbent assay; female; follow up; headache; hospital admission; hospitalization; human; intensive care; interview; major clinical study; male; middle aged; mortality rate; nonhuman; pandemic; pneumonia; prevalence; rheumatic disease; rheumatology; seroconversion; serology; Severe acute respiratory syndrome coronavirus 2; summer; tertiary care center
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
Language:
English
Journal:
Annals of the Rheumatic Diseases
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS